Stocknear Logo Stocknear
/
Popular
Login

Sangamo Therapeutics Inc.

0.82
-0.04 (-4.35%)
At close: Mar 28, 2025, 3:59 PM
0.84
2.14%
After-hours: Mar 28, 2025, 06:51 PM EDT
-4.35%
Bid 0.81
Market Cap 184.78M
Revenue (ttm) 64.39M
Net Income (ttm) -109.11M
EPS (ttm) -0.49
PE Ratio (ttm) -1.68
Forward PE -5.19
Analyst Buy
Ask 0.84
Volume 1,859,094
Avg. Volume (20D) 5,966,196
Open 0.85
Previous Close 0.86
Day's Range 0.82 - 0.85
52-Week Range 0.30 - 3.18
Beta 1.50

About SGMO

Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes; and ...

[Show more]
Industry Biotechnology
Sector Healthcare
IPO Date Apr 6, 2000
Employees 183
Stock Exchange NASDAQ
Ticker Symbol SGMO
Website https://www.sangamo.com
Full Company Profile

Analyst Forecast

According to 6 analyst ratings, the average rating for SGMO stock is "Buy." The 12-month stock price forecast is $4, which is an increase of 386.44% from the latest price.

Stock Forecasts

Why Price Moved

Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
1 week ago
+2.94%
Sangamo Therapeutics shares are trading lower afte... Unlock content with Pro Subscription
2 months ago
-56.41%
Sangamo Therapeutics shares are trading lower after Wells Fargo cut its price target on the stock from $3 to $2.
news image

1 week ago · seekingalpha.com

Sangamo Therapeutics, Inc. (SGMO) Q4 2024 Earnings Call Transcript

Sangamo Therapeutics, Inc. (NASDAQ:SGMO ) Q4 2024 Earnings Conference Call March 17, 2025 4:30 PM ET Company Participants Louise Wilkie - Vice President, Investor Relations and Corporate Communication...

news image

1 week ago · zacks.com

Sangamo Therapeutics (SGMO) Reports Q4 Loss, Misses Revenue Estimates

Sangamo Therapeutics (SGMO) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.34 per share a year ago.

news image

3 weeks ago · businesswire.com

Sangamo Therapeutics Announces Fourth Quarter and Full Year 2024 Earnings Call and Participation in Upcoming Investor Conference

RICHMOND, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2024 EARNINGS CALL AND PARTICIPATION IN UPCOMING INVESTOR CONFERENCE.

news image

1 month ago · businesswire.com

Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety Profile

RICHMOND, Calif.--(BUSINESS WIRE)--SANGAMO ANNOUNCES UPDATED PHASE 1/2 STAAR STUDY DATA IN FABRY SHOWING SUSTAINED BENEFIT, IMPROVEMENTS IN KIDNEY FUNCTION AND FAVORABLE SAFETY PROFILE.

news image

1 month ago · accessnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc. - SGMO

NEW YORK, NY / ACCESS Newswire / February 5, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sangamo Therapeutics, Inc. ("Sangamo" or the "Company") (NASDAQ:SGMO). Such investor...

news image

1 month ago · accessnewswire.com

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc. - SGMO

NEW YORK, NY / ACCESS Newswire / February 1, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sangamo Therapeutics, Inc. ("Sangamo" or the "Company") (NASDAQ:SGMO). Such investor...

news image

2 months ago · accessnewswire.com

Sangamo Therapeutics, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Sangamo Therapeutics, Inc. (SGMO)

NEW YORK CITY, NY / ACCESS Newswire / January 17, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sangamo Therapeutics, Inc. ("Sangamo Therapeutics, Inc.") (NASDAQ...

news image

2 months ago · businesswire.com

Securities Fraud Investigation Into Sangamo Therapeutics, Inc. (SGMO) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Sangamo Therapeutics, Inc...

news image

2 months ago · businesswire.com

Sangamo Therapeutics, Inc. (SGMO) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Sangamo Therapeutics, Inc. (“Sangamo” or the “Company”) (NASDAQ: SGMO) investors concerning the C...

news image

2 months ago · businesswire.com

Securities Fraud Investigation Into Sangamo Therapeutics, Inc. (SGMO) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Sangamo Therapeutics, Inc. (“Sangamo” or the “Company”) (NASDAQ: SGMO) on behalf of investors concerning th...

Create Price Alert on SGMO

Your price alert will notify you when the stock price is above 0.82.

Add to Watchlist